{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:30:06Z","timestamp":1789745406246,"version":"4.0.1"},"reference-count":20,"publisher":"American Society of Hematology","issue":"13","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,28]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Among 281 patients with essential thrombocythemia and calreticulin (CALR) mutation, we found a variant allele frequency of \u226560% to be associated with significantly shortened myelofibrosis-free survival, mostly apparent with CALR type-1 and CALR type-indeterminate mutations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023023428","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T21:12:17Z","timestamp":1705957937000},"page":"1310-1314","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["<i>CALR<\/i> mutation burden in essential thrombocythemia and disease outcome"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"Paola","family":"Guglielmelli","sequence":"first","affiliation":[{"name":"1Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-6171","authenticated-orcid":false,"given":"Natasha","family":"Szuber","sequence":"additional","affiliation":[{"name":"2University of Montreal, Montreal, QC, Canada"},{"name":"3Quebec CML-MPN Research Group, Montreal, QC, Canada"},{"name":"4Department of Hematology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9104-6172","authenticated-orcid":false,"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Capecchi","sequence":"additional","affiliation":[{"name":"1Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Maccari","sequence":"additional","affiliation":[{"name":"1Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Harnois","sequence":"additional","affiliation":[{"name":"3Quebec CML-MPN Research Group, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Karrar","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maymona","family":"Abdelmagid","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjola","family":"Balliu","sequence":"additional","affiliation":[{"name":"1Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nacca","sequence":"additional","affiliation":[{"name":"1Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Atanasio","sequence":"additional","affiliation":[{"name":"1Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Sestini","sequence":"additional","affiliation":[{"name":"1Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9468-628X","authenticated-orcid":false,"given":"Audrey","family":"D\u00e9silets","sequence":"additional","affiliation":[{"name":"2University of Montreal, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6241-1206","authenticated-orcid":false,"given":"Giuseppe Gaetano","family":"Loscocco","sequence":"additional","affiliation":[{"name":"1Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Rotunno","sequence":"additional","affiliation":[{"name":"1Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5375-3749","authenticated-orcid":false,"given":"Lambert","family":"Busque","sequence":"additional","affiliation":[{"name":"2University of Montreal, Montreal, QC, Canada"},{"name":"4Department of Hematology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4605-3821","authenticated-orcid":false,"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5755-0730","authenticated-orcid":false,"given":"Alessandro Maria","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"1Department of Experimental and Clinical Medicine, Center of Research and Innovation of Myeloproliferative Neoplasms, Division of Hematology, Azienda Ospedaliera Universitaria Careggi, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"25","key":"2024032815211098400_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"2024032815211098400_bib2","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024032815211098400_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-023-00786-x","article-title":"Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis","volume":"13","author":"Guglielmelli","year":"2023","journal-title":"Blood Cancer J"},{"issue":"5","key":"2024032815211098400_bib4","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.3324\/haematol.2018.202952","article-title":"Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease","volume":"104","author":"Stengel","year":"2019","journal-title":"Haematologica"},{"issue":"7","key":"2024032815211098400_bib5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2024032815211098400_bib6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2024032815211098400_bib7","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ajh.26821","article-title":"The International Consensus Classification of myeloid neoplasms and acute leukemias: myeloproliferative neoplasms","volume":"98","author":"Thiele","year":"2023","journal-title":"Am J Hematol"},{"issue":"2","key":"2024032815211098400_bib8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for myelofibrosis research and treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"2024032815211098400_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"2024032815211098400_bib10","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 vs type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"issue":"10","key":"2024032815211098400_bib11","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2024032815211098400_bib12","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2024032815211098400_bib13","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"issue":"6","key":"2024032815211098400_bib14","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A\u00a0prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2024032815211098400_bib15","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ajh.26332","article-title":"Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: a multicenter study involving 1607 patients","volume":"96","author":"Loscocco","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"2024032815211098400_bib16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2024032815211098400_bib17","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A\u00a0prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"2024032815211098400_bib18","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00277-021-04717-3","article-title":"Clinical effect of CALR allele burden in patients with essential thrombocythemia","volume":"101","author":"Bertozzi","year":"2022","journal-title":"Ann Hematol"},{"issue":"10","key":"2024032815211098400_bib19","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"suppl 1","key":"2024032815211098400_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood-2022-159435","article-title":"Discovery of INCA033989, a monoclonal antibody that selectively antagonizes mutant calreticulin oncogenic function in myeloproliferative neoplasms (MPNs)","volume":"140","author":"Reis","year":"2022","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/13\/1310\/2218668\/blood_bld-2023-023428-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/13\/1310\/2218668\/blood_bld-2023-023428-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T15:21:41Z","timestamp":1711639301000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/13\/1310\/514710\/CALR-mutation-burden-in-essential-thrombocythemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":20,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,3,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023023428","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]}}}